Aoun, EG, Christopher, PP, Ingraham, JW. Emerging drugs of abuse: clinical and legal considerations. Rhode Island Medical Journal
2014; 97: 41–45.
Baumann, MH, et al.
Bath salts, spice and related designer drugs: the science behind the headlines. Journal of Neuroscience
2014; 34: 15150–15168.
Johnson, PS, Johnson, MW. Investigation of ‘bath salts’ use patterns within an online sample of users in the United States. Journal of Psychoactive Drugs
2014; 46: 369–378.
Schneir, A, et al.
Comprehensive analysis of ‘bath salts’ purchased from California stores and the internet. Clinical Toxicology (Philadelphia)
2014; 52: 651–658.
Araujo, AM, et al.
Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of ‘legal high’ packages containing synthetic cathinones. Archives of Toxicology
2015; 89: 757–711.
Iversen, L, et al.
Neurochemical profiles of some novel psychoactive substances. European Journal of Pharmacology
2013; 700: 147–51.
Belton, P, et al.
Cardiac infection and sepsis in 3 intravenous bath salts drug users. Clinical Infectious Diseases
2013; 56: e102-e104.
Banks, ML, et al.
Synthetic cathinones (‘bath salts’). Journal of Emergency Medicine
2014; 46: 632–642.
Hohmann, N, Mikus, G, Czock, D. Effects and risks associated with novel psychoactive substances: mislabelling and sale as bath salts, spice and research chemicals. Deutsches Arzteblatt International
2014; 111: 139–147.
Martinez-Clemente, J, et al.
Dose and time-dependent selective neurotoxicity induced by mephedrone in mice. PLoS ONE
2014; 9: e99002.
Dorairaj, JJ, et al.
The untold truth about ‘bath salt’ highs: a case series demonstrating local tissue injury. Journal of Plastic, Reconstructive and Aesthetic Surgery
2012; 65: e37–e41.
Russo, R, et al.
Life-threatening necrotizing fasciitis due to ‘bath salts’ injection. Orthopedics
2012; 35: e124–127.
Thwaites, GE, et al.
Clinical management of Staphylococcus aureus bacteraemia. Lancet Infectious Diseases
2011; 11: 208–222.
van Hal, SJ, et al.
Predictors of mortality in Staphylococcus aureus bacteraemia. Clinical Microbiology Reviews
2012; 25: 362–386.
Kobayashi, D, et al.
A predictive rule for mortality of inpatients with Staphylococcus aureus bacteraemia: a classification and regression tree analysis. European Journal of Internal Medicine
2014, 25: 914–918.
Fortuin-de Smidt, MC, et al.
Staphylococcus aureus bacteraemia in Gauteng academic hospitals, South Africa. International Journal of Infectious Diseases
Jensen, AG, et al.
Treatment and outcome of Staphylococcus aureus bacteraemia: a prospective study of 278 cases. Archives of Internal Medicine
2002; 162: 25–32.
Ye, R, et al.
Clinical characteristics of septic pulmonary embolism in adults. Respiratory Medicine
2014; 108: 1–8.
Holland, TL, Arnold, C, Fowler, VG. Jr.
Clinical management of Staphylococcus aureus bacteraemia: a review. Journal of the American Medical Association
2014; 312: 1330–1341.
Lopez-Cortes, LE, et al.
Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus infection. Clinical Infectious Diseases
2013; 57: 1225–1233.
Gould, FK, et al.
Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. Journal of Antimicrobial Chemotherapy
2009; 63: 849–861.
Health Protection Scotland. Weekly report (13 January 2015) including commentary on quarterly epidemiological data on Staphylococcus aureus (S. aureus) bacteraemia infection in Scotland, July to September (Q3) 2014 (http://www.hps.scot.nhs.uk/documents/ewr/pdf2015/1502.pdf). Accessed 9 June 2015.
Harmsen, D, et al.
Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. Journal of Clinical Microbiology
2003; 41: 5442–5448.
Lina, G, et al.
Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clinical Infectious Diseases
1999; 29: 1128–1132.
Brett, MM, et al.
Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. Epidemiology and Infection
2005; 133: 575–582.
Grundmann, H, et al.
The dynamic changes of dominant clones of Staphylococcus aureus causing bloodstream infections in the European region: results of a second structured survey. Eurosurveillance
2014; 19: pii 20987.
Bassetti, S, Battegay, M.
Staphylococcus aureus infections in injection drug users: risk factors and prevention strategies. Infection
2004; 32: 163–169.